COPD药物及新靶点研究进展

IF 0.8 Q4 MATERIALS SCIENCE, BIOMATERIALS Nano Life Pub Date : 2021-09-01 DOI:10.1142/s1793984421400080
Lveli Wang, Chuan Xiao, Yaping Liang, Zhiying Weng, Weimin Yang
{"title":"COPD药物及新靶点研究进展","authors":"Lveli Wang, Chuan Xiao, Yaping Liang, Zhiying Weng, Weimin Yang","doi":"10.1142/s1793984421400080","DOIUrl":null,"url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) is the third-most deadly disease in the world and will be a major healthcare problem for decades to come. Its etiology is mainly related to the exposure to cigarette smoke and poisonous gases, and the infections of viruses including COVID-19 induce acute exacerbation of COPD, which may cause death in patients. Few advances have been made in COPD pathological mechanism, and the current clinical treatment strategies focus on both bronchodilator and anti-inflammatory interventions; but with limited clinical therapeutic agents, COPD therapies still lack more drugs especially those that antagonize COPD-specific inflammatory responses. We review the COPD clinically applied drugs, and the progress of research on new drugs and related novel targets, including [Formula: see text] agonists and anti-muscarinic drugs for airway diastole, glucocorticoids and phosphodiesterase-4 inhibitors for anti-inflammatory, protease inhibitors, emerging antioxidants, adhesion factor inhibitors, growth factor antagonists, adenylate cyclase agonists, chemokine antagonists, etc. We thus provide insights on the COPD new drugs research and development.","PeriodicalId":44929,"journal":{"name":"Nano Life","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Research Advances in COPD Drugs and Novel Targets\",\"authors\":\"Lveli Wang, Chuan Xiao, Yaping Liang, Zhiying Weng, Weimin Yang\",\"doi\":\"10.1142/s1793984421400080\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic obstructive pulmonary disease (COPD) is the third-most deadly disease in the world and will be a major healthcare problem for decades to come. Its etiology is mainly related to the exposure to cigarette smoke and poisonous gases, and the infections of viruses including COVID-19 induce acute exacerbation of COPD, which may cause death in patients. Few advances have been made in COPD pathological mechanism, and the current clinical treatment strategies focus on both bronchodilator and anti-inflammatory interventions; but with limited clinical therapeutic agents, COPD therapies still lack more drugs especially those that antagonize COPD-specific inflammatory responses. We review the COPD clinically applied drugs, and the progress of research on new drugs and related novel targets, including [Formula: see text] agonists and anti-muscarinic drugs for airway diastole, glucocorticoids and phosphodiesterase-4 inhibitors for anti-inflammatory, protease inhibitors, emerging antioxidants, adhesion factor inhibitors, growth factor antagonists, adenylate cyclase agonists, chemokine antagonists, etc. We thus provide insights on the COPD new drugs research and development.\",\"PeriodicalId\":44929,\"journal\":{\"name\":\"Nano Life\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2021-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nano Life\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1142/s1793984421400080\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano Life","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/s1793984421400080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 4

摘要

慢性阻塞性肺病(COPD)是世界上第三致命的疾病,在未来几十年将是一个主要的医疗问题。其病因主要与接触香烟烟雾和有毒气体有关,而包括新冠肺炎在内的病毒感染会导致慢性阻塞性肺病急性加重,并可能导致患者死亡。在COPD的病理机制方面进展甚微,目前的临床治疗策略集中在支气管扩张剂和抗炎干预;但由于临床治疗药物有限,COPD治疗仍然缺乏更多的药物,尤其是那些拮抗COPD特异性炎症反应的药物。我们综述了COPD的临床应用药物,以及新药和相关新靶点的研究进展,包括[配方:见正文]用于气道舒张期的激动剂和抗毒蕈碱药物,用于抗炎的糖皮质激素和磷酸二酯酶-4抑制剂,蛋白酶抑制剂,新兴抗氧化剂,粘附因子抑制剂,生长因子拮抗剂,腺苷酸环化酶激动剂,从而为COPD新药的研究和开发提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Research Advances in COPD Drugs and Novel Targets
Chronic obstructive pulmonary disease (COPD) is the third-most deadly disease in the world and will be a major healthcare problem for decades to come. Its etiology is mainly related to the exposure to cigarette smoke and poisonous gases, and the infections of viruses including COVID-19 induce acute exacerbation of COPD, which may cause death in patients. Few advances have been made in COPD pathological mechanism, and the current clinical treatment strategies focus on both bronchodilator and anti-inflammatory interventions; but with limited clinical therapeutic agents, COPD therapies still lack more drugs especially those that antagonize COPD-specific inflammatory responses. We review the COPD clinically applied drugs, and the progress of research on new drugs and related novel targets, including [Formula: see text] agonists and anti-muscarinic drugs for airway diastole, glucocorticoids and phosphodiesterase-4 inhibitors for anti-inflammatory, protease inhibitors, emerging antioxidants, adhesion factor inhibitors, growth factor antagonists, adenylate cyclase agonists, chemokine antagonists, etc. We thus provide insights on the COPD new drugs research and development.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nano Life
Nano Life MATERIALS SCIENCE, BIOMATERIALS-
CiteScore
0.70
自引率
12.50%
发文量
14
期刊最新文献
Nanotherapeutic Approaches for the Treatment of Rheumatoid Arthritis Taming of Organic Pollutants Using Covalent-Organic-Framework-based Materials: Challenges and Future Prospects HSP90 antisense oligonucleotide enhances the inhibitory effect of photothermal therapy on triple-negative breast cancer cells Amoxicillin Degradation and Antimutagenic Potential of Phytofabricated Silver Nanoparticles Doped Polyurethane Membrane for Wastewater Treatment A Critical Review on Nanotechnology: A Technique in Cancer Detection and Prophylaxis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1